How we generate value

Rejuvenate Biomed, how we generate value image

Building an exciting pipeline

Rejuvenate Biomed pipeline

  

Rejuvenate Biomed One-Pager

Highlights

Rejuvenate Biomed Completes Last Patient Visit in Phase 2 Trial of RJx-01 in COPD-Related Muscle Weakness and Advances Regulatory Discussions for Sarcopenia

Last patient has completed the final study visit in the Phase 2 trial in older adults with COPD-induced muscle weakness, and is on track to report topline data by year-end 2026. Placebo-controlled Phase 2 trial is assessing RJx-01’s safety profile and its effects on muscle strength, physical function and muscle fatigue resistance. Productive discussions with regulatory authorities to define the development pathway for RJx-01 in sarcopenia are ongoing.
LEARN MORE

Rejuvenate Biomed Completes Recruitment in Phase 2 Trial Assessing First-in-Class Multi-Pathway Therapeutic RJx-01 in COPD-Induced Sarcopenia

Fully recruited Phase 2 trial evaluates RJx-01 in older adults with COPD-induced muscle weakness and sarcopenia, an area with no approved pharmacologic treatments. RJx-01 offers a multi-pathway approach targeting several drivers of muscle decline, including mitochondrial dysfunction, inflammation, fibrosis and neuromuscular impairment. Topline data expected by year-end 2026 represents a near-term clinical inflection point for Rejuvenate Biomed’s lead asset and further platform validation.
LEARN MORE

Rejuvenate Biomed Completes Last Patient Visit in Phase 2 Trial of RJx-01 in COPD-Related Muscle Weakness and Advances Regulatory Discussions for Sarcopenia

Last patient has completed the final study visit in the Phase 2 trial in older adults with COPD-induced muscle weakness, and is on track to report topline data by year-end 2026. Placebo-controlled Phase 2 trial is assessing RJx-01’s safety profile and its effects on muscle strength, physical function and muscle fatigue resistance. Productive discussions with regulatory authorities to define the development pathway for RJx-01 in sarcopenia are ongoing.
LEARN MORE

Acknowledgements and investors